Molbio Diagnostics

What Molbio Diagnostics does

Molbio Diagnostics is an India-based molecular diagnostics company that designs, manufactures, and commercializes portable, battery-operated real-time PCR platforms — most notably its proprietary Truenat system developed in-house through wholly-owned subsidiary Bigtec Labs — to bring lab-grade molecular testing to primary healthcare and community settings. The Truenat platform anchors an extensive assay menu covering tuberculosis (TB), COVID-19, HPV, hepatitis, HIV, malaria, dengue, chikungunya, scrub typhus, Nipah, and other infectious diseases, and is complemented by AI-enabled portable X-ray (ProRad Atlas, via Prognosys Medical Systems), digital pathology whole-slide imaging (OptraScan, via OptraSCAN Inc.), AI-assisted sputum microscopy (BactoSiA), and a distribution partnership for the iBreastExam radiation-free breast screening device (UE LifeSciences).

The company monetizes through hardware sales of diagnostic devices and recurring consumables (assay cartridges and test kits), supplemented by digital pathology subscriptions and channel distribution revenue. Its customer base is concentrated in government health programs — including national TB programs, health ministries, and international organizations (WHO, Stop TB Partnership TB REACH, Global Fund/Global Drug Facility, Africa CDC) — across 80+ countries with a deployed base of more than 10,000 devices and 40+ million tests performed. WHO endorsement as an initial test for TB and MDR-TB, WHO-IARC validation for its HPV test, CE MDR certification for digital radiology, and ISO 13485/27001 and SOC2 Type 2 compliance underpin its regulatory positioning.

Founded in 2000 and headquartered in Verna, Goa, Molbio achieved unicorn status in September 2022 at a $1.6 billion post-money valuation following an $85 million round led by Temasek with Motilal Oswal Alternates, and has since expanded through the 2023 acquisition of a 70% stake in Prognosys Medical Systems and the 2024 acquisition of a majority stake in OptraSCAN Inc. for $30 million. The company filed its Draft Red Herring Prospectus with SEBI in August 2025 and received IPO approval in December 2025, marking its transition toward a public listing.

Name

Molbio Diagnostics

Legal name

Molbio Diagnostics Limited

Website

https://molbiodiagnostics.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Molbio Diagnostics is an India-based molecular diagnostics company that manufactures portable, battery-operated real-time PCR platforms (Truenat) and complementary AI-enabled imaging and digital pathology solutions, serving government health programs and international organizations across 80+ countries for point-of-care TB, infectious disease, and cancer screening.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics / Point-of-Care Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industries

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL)

Keywords

• Molecular diagnostics
• Point-of-care testing
• Portable PCR devices
• Infectious disease diagnostics
• Tuberculosis screening

Headquarters

HQ city

Verna

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. Diagnostic Devices and Consumables Sales: Molbio generates revenue through sale of Truenat portable molecular diagnostic devices and associated assay cartridges/test kits. The company manufactures and sells diagnostic platforms along with disease-specific test kits for TB, COVID-19, HPV, hepatitis, malaria, and other infectious diseases to government health programs, healthcare facilities, and through distribution partnerships.
2. Digital Pathology Solutions: Revenue from OptraScan digital pathology portfolio including whole slide imaging scanners (OS Ultra, OS-Lite, OS-SiX, OS-FS, OS-Fli models), software subscriptions for cloud-based platform access, and LIS integration services for pathology laboratories and hospitals.
3. iBreastExam Device Distribution: Distribution partnership revenue through UE LifeSciences collaboration for FDA-cleared iBreastExam radiation-free breast screening device across 50+ developing countries in India, Africa, Middle East, CIS, Philippines, Indonesia, and Vietnam.

Pricing tiers

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Core offering

Molbio Diagnostics manufactures and sells portable, battery-operated molecular diagnostic devices (Truenat real-time PCR platform) along with disease-specific assay cartridges for tuberculosis, COVID-19, HPV, hepatitis, malaria, and other infectious diseases. The company also offers AI-enabled portable X-ray systems (ProRad Atlas), digital pathology solutions (OptraScan), and distributes the iBreastExam radiation-free breast screening device, targeting government health programs and healthcare facilities in resource-limited settings across 80+ countries.

Product overview

Molbio Diagnostics operates as a platform-plus-products portfolio company centered on its Truenat portable molecular diagnostic platform. The core Truenat system is a battery-operated real-time PCR device that serves as the foundation for an extensive menu of assay modules covering infectious diseases (TB, COVID-19, hepatitis, HPV, malaria, dengue, Nipah, and more). The portfolio is augmented by acquired and partnered technologies: Prognosys Medical Systems (70% stake, 2023) contributes AI-driven portable X-ray systems (ProRad Atlas), and OptraSCAN Inc. (majority stake, 2024) provides digital pathology whole-slide imaging solutions. A distribution partnership with UE LifeSciences adds the iBreastExam radiation-free breast screening device. Together, these products enable end-to-end decentralized healthcare delivery—from AI-powered imaging screening to confirmatory molecular diagnostics to digital pathology—targeting point-of-care settings in over 80 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Truenat: Portable real-time PCR molecular diagnostic platform for point-of-care testing of infectious diseases including TB, COVID-19, HPV, hepatitis, and other pathogens. WHO-endorsed battery-operated PCR device.
• Truenat Assays
• iBreastExam
• ProRad Atlas Ultraportable
• OptraScan
• BactoSiA
• iBreastExam (distributed)

Products and services

• Truenat A portable, battery-operated real-time PCR diagnostic platform that enables rapid, accurate molecular testing at the point of care without requiring sophisticated laboratory infrastructure. Supports testing for multiple infectious diseases including TB, COVID-19, HPV, hepatitis, and neglected tropical diseases. Designed for government health programs, national TB programs, and rural healthcare facilities in resource-limited settings.
• Truenat Assays A comprehensive portfolio of molecular diagnostic assay kits designed for use exclusively on the Truenat platform, covering infectious diseases such as tuberculosis, hepatitis, HPV, malaria, dengue, chikungunya, scrub typhus, Nipah, and respiratory infections. Sold as consumables that drive recurring revenue per installed device.
• iBreastExam A radiation-free, handheld device that uses advanced sensor technology to electronically palpate breast tissue and detect non-palpable lumps as small as 0.5 cm without requiring user interpretation. Distributed in partnership with UE LifeSciences across 50+ developing countries including India, Africa, Middle East, CIS, Philippines, Indonesia, and Vietnam.
• ProRad Atlas Ultraportable An AI-driven portable digital X-ray system developed by subsidiary Prognosys Medical Systems, featuring ultra-portable design for deployment in remote and underserved areas. Received CE MDR certification from TÜV SÜD for medical imaging compliance. Used in combination with CAD4TB software for community TB screening.
• OptraScan A digital pathology solution that digitizes histopathology workflows using whole slide imaging scanners (OS Ultra, OS-Lite, OS-SiX, OS-FS, OS-Fli models), integrated analytical software, and secure cloud-based infrastructure. Converts glass slides to high-resolution digital images for remote consultation, collaborative review, AI-powered analysis, and LIS integration. Targets pathology laboratories and hospitals.

Quantifiable outcome

• 82.2% of TB patients began treatment same day using Truenat versus 3% with off-site GeneXpert testing (Lancet study in Tanzania and Mozambique)
• +5 more outcomes

Named customers10 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and major.

• AIIMS (All India Institute of Medical Sciences)coreStrategic or Co-development Partner · 1 June 2026AIIMS New Delhi collaborated with Molbio Diagnostics for validation of Truenat HPV-HR Plus indigenous HPV test. AIIMS led the multi-center study published in International Journal of Cancer alongside three ICMR institutes and WHO-IARC.
• ICMR (Indian Council of Medical Research)coreStrategic or Co-development Partner · 1 June 2026ICMR institutes participated in validation study for Truenat HPV-HR Plus alongside AIIMS and WHO-IARC. ICMR also signed 41 public health tech transfer deals with industry including technology transfers for TB and other disease diagnostics.
• WHO IARC (International Agency for Research on Cancer)coreStrategic or Co-development Partner · 1 June 2026WHO-IARC validated Truenat HPV-HR Plus as India's first indigenous HPV test meeting international validation criteria. IARC is conducting field studies in rural Tamil Nadu to inform rollout decisions across low- and middle-income countries.
• Africa CDCmajorStrategic or Co-development Partner · 1 January 2026Molbio is working with Africa CDC to combat Ebola outbreak by deploying rapid diagnostic tests. Tests have reached affected regions in Uganda and DRC, with company beginning validation on clinical specimens.
• UE LifeSciencescoreChannel Partner/ Reseller/ Distributor · 16 September 2025Molbio partnered with UE LifeSciences to distribute the FDA-cleared iBreastExam radiation-free handheld breast cancer screening device across more than 50 developing countries including India, Africa, Middle East, CIS countries, Philippines, Indonesia, and Vietnam. The partnership leverages Molbio's extensive distribution network.
• OptraSCAN Inc.coreStrategic or Co-development Partner · 1 November 2024Molbio acquired majority stake in OptraSCAN Inc. for $30 million. OptraSCAN is a digital pathology company providing whole slide imaging scanners and AI-enabled pathology solutions, expanding Molbio's portfolio beyond molecular diagnostics into digital pathology.
• Prognosys Medical SystemscoreStrategic or Co-development Partner · 20 February 2023Molbio acquired 70% stake in Bengaluru-based Prognosys Medical Systems, a manufacturer of digital radiology solutions including AI-driven portable X-ray units. This enables combined offerings of Truenat molecular diagnostics with AI-driven radiology for integrated disease screening and diagnosis targeting TB and COVID-19.
• Stop TB PartnershipcoreStrategic or Co-development PartnerStop TB Partnership awarded Molbio the Kochon Prize 2024 and supports deployment through TB REACH initiative. Stop TB Partnership's Introducing New Tools Project (iNTP) has deployed Truenat across multiple countries with USAID funding.
• Bigtec LabscoreTechnology or IntegrationBigtec Labs is Molbio's wholly-owned R&D subsidiary based in Goa, responsible for design and development of Truenat and other diagnostic platforms. All proprietary technology is developed through this subsidiary.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Cepheid (Danaher): Cepheid's GeneXpert is the dominant molecular TB diagnostic platform globally and the primary benchmark against which Molbio's Truenat is clinically compared (per the Lancet study). Both companies sell cartridge-based PCR systems targeting TB and infectious disease testing at POC settings, with Cepheid holding the entrenched installed base.

Broad incumbents

• Abbott Diagnostics: Abbott offers molecular diagnostics through m2000 and ID NOW platforms serving infectious disease testing globally. While not POC-focused like Truenat, Abbott has broader menus, larger hospital channel presence, and greater resources for competing on emerging market tenders.
• Hologic: Hologic's Panther and Aptima molecular systems serve women's health and infectious disease diagnostics. Comparable in molecular assay technology and certain disease areas (HPV, STI), Hologic competes for hospital laboratory tenders that overlap with Molbio's emerging institutional footprint.
• Qiagen: Qiagen's QIAstat-Dx and NeuMoDx molecular diagnostic platforms compete in infectious disease testing with syndromic panel capabilities. Qiagen has a strong global distribution network and established relationships with reference labs, posing competitive risk in non-POC segments.
• bioMérieux (BioFire): bioMérieux's BioFire FilmArray syndromic panels lead the molecular infectious disease diagnostics market with comprehensive respiratory, GI, and meningitis/encephalitis panels. While more centralized-lab oriented, BioFire competes for the same hospital budget allocation as Molbio's Truenat.
• Roche Diagnostics: Roche offers the cobas Liat and cobas 6800/8800 molecular systems covering infectious disease testing. As the largest diagnostics player globally, Roche competes in both POC and centralized lab segments, with extensive emerging market reach through its established commercial infrastructure.
• Becton Dickinson (BD): BD's MAX System and FACSDiscover molecular and flow cytometry platforms compete across infectious disease and women's health diagnostics. BD has deep global distribution and competes for the same molecular diagnostics procurement budgets as Molbio.
• Danaher Corporation (Cepheid parent): Danaher owns Cepheid (GeneXpert) and operates the broader Diagnostics platform including Beckman Coulter, Leica Biosystems, and Radiometer. As a $150B+ science and technology conglomerate, Danaher has unmatched resources to invest in GeneXpert platform enhancements that could pressure Molbio's differentiation.

Emerging players

• Cue Health: Cue Health developed a connected POC molecular testing platform with focus on at-home and clinical settings. Comparable in miniaturization philosophy and consumer-grade form factor, though Cue has faced significant commercial challenges since COVID-19 demand waned.
• Mammoth Biosciences: Mammoth Biosciences is developing CRISPR-based POC molecular diagnostic platforms targeting infectious disease. While still pre-commercial, Mammoth represents a potential next-generation technology platform that could compete with Truenat's PCR-based architecture in coming years.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/molbiodx
• Facebookfacebook.com/molbiodx
• LinkedInlinkedin.com/company/molbio-diagnostics
• Instagraminstagram.com/molbiodx

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Molbio Diagnostics